Figure 1

A. Western blot analysis for hPXR1.2 and hPXR1 antibodies. With hPXR1.2 antibody, in MCF-7 cells were detected mainly two bands at 40 and 70 kDa; however, in MDA-MB-231 can be also observed additional bands at 28 and 90 kDa. In this last cell line, with hPXR1 antibody multiple bands at 28, 37, 40, 70, 120 and 250 kDa; however, in MCF-7 were only detected bands at 70, 120 and 250 kDa. In benign breast diseases no bands were observed either with hPXR1.2 or with hPXR1 antibody. In carcinomas in situ, bands at 50, 100 and 160 kDa were observed with both antibodies. In infiltrative carcinomas, those samples incubated with hPXR1.2 presented multiple bands at approximately 40, 50 and 70 kDa.; while in samples incubated with hPXR1 antibody, five immunoreactive bands at 40, 50, 70, 120 and 250 kDa were observed. B. Western blot analysis for RXRs antibodies. For RXR-α, RXR-β and RXR-γ, only a single band at 60 kDa of molecular weight was found in all pathologies studied. For all figures: Lane 1: MCF-7 cells. Lane 2: MDA-MB-231 cells. Lane 3: benign breast diseases. Lane 4: Ductal carcinoma in situ. Lanes 5 and 6: Lobular carcinoma in situ. Lane 7: Infiltrative ductal carcinoma. Lane 8: Infiltrative lobular carcinoma. Each blot is representative of its respective group. After stripping, immunoreactivity with an anti-actin antibody was used as loading control (actin, bottom panels).